Skip to main content
Login
Contact
Subscribe
Search form
Search
The Punxsutawney Spirit
Home
Forms
Delivery Concerns
News
Sports
Obituaries
Classifieds
Place an Ad
Classified Display Ads
Service Directory
Photos
Videos
Games
Entertainment
Local Guide
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Nektar Therapeutics
(NQ:
NKTR
)
17.87
USD
-0.23 (-1.27%)
Official Closing Price
/ Updated:
7:59 PM EDT, Aug 19, 2019
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
3,642,300
Open
18.31
Bid (Size)
17.77 (5)
Ask (Size)
18.00 (3)
Prev. Close
18.10
Today's Range
17.56 - 18.33
52wk Range
17.30 - 69.76
Shares Outstanding
171,402,476
Dividend Yield
N/A
Performance
YTD
-47.78%
-47.78%
1 Month
-44.74%
-44.74%
3 Month
-44.62%
-44.62%
6 Month
-58.26%
-58.26%
1 Year
-70.51%
-70.51%
Top News
More News
Bragar Eagel & Squire, P.C. is Investigating Nektar Therapeutics, Inc. (NASDAQ: NKTR) on Behalf of Stockholders and Encourages Nektar Investors to Contact the Firm
August 15, 2019
Bragar Eagel & Squire, P.C. is investigating potential claims against Nektar Therapeutics, Inc. (NASDAQ: NKTR). Our investigation concerns whether Nektar has violated the federal securities laws and/or...
Read More
from
PR Newswire
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
August 14, 2019
from
GlobeNewswire News Releases
More News
Read More
Glancy Prongay & Murray LLP Files a Securities Class Action on Behalf of Nektar Therapeutics Investors (NKTR)
August 19, 2019
from
Business Wire News Releases
Cancer Drug Sales Expected to Exceed $230 Billion by 2024
August 13, 2019
from
PR Newswire
Cancer Drug Sales Expected to Exceed $230 Billion by 2024
August 13, 2019
category
Featured News
from
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
August 13, 2019
from
Business Wire News Releases
Valley National Bancorp Larger Than S&P 500 Component Nektar Therapeutics
August 15, 2019
category
Stocks
from
Market News Video
Nektar Therapeut Shares Down 44.9% Since SmarTrend's Sell Call (NKTR)
August 14, 2019
from
Comtex SmarTrend® News Briefs
Umpqua Holdings Larger Than S&P 500 Component Nektar Therapeutics
August 13, 2019
category
Stocks
from
Market News Video
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nektar Therapeutics (NKTR)
August 14, 2019
from
PR Newswire
United Therapeutics Larger Than S&P 500 Component Nektar Therapeutics
August 13, 2019
category
Stocks
from
Market News Video
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
